AGENT ENHANCING LIPID-LOEWRING EFFECT
It is intended to provide a drug which has an excellent effect of inhibiting the secretion of apoB-related lipoproteins and enhances the lipid-lowering effect of another lipid-lowering agent, i.e., an agent enhancing lipid-lowering effect. It is found out that a derivative having tetrahydropyran rep...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English French Japanese |
Published |
09.06.2005
|
Edition | 7 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | It is intended to provide a drug which has an excellent effect of inhibiting the secretion of apoB-related lipoproteins and enhances the lipid-lowering effect of another lipid-lowering agent, i.e., an agent enhancing lipid-lowering effect. It is found out that a derivative having tetrahydropyran represented by the following general formula (I): (I) wherein each symbol is as defined in the description; has a potent activity of inhibiting the secretion of apoB-related lipoproteins and can enhance the lipid-lowering effect of another lipid-lowering agent, when used together with such an agent. When used together with another lipid-lowering agent, the above drug is useful as an agent enhancing lipid-lowering effect for familial hypercholesterolemia and a remedy for intractable hyperlipemia with the coincidence of diabetes.
L'invention concerne un agent renforçant l'effet hypolipidémiant, à savoir un médicament présentant un excellent effet d'inhibition de la sécrétion des lipoprotéines associées à apoB, et renforçant l'effet hypolipidémiant d'un autre agent hypolipidémiant. Selon l'invention, un dérivé contenant du tétrahydropyrane, représenté par la formule générale (I) : (I), dans laquelle chaque symbole est tel que défini dans la description, présente une activité puissante d'inhibition de la sécrétion des lipoprotéines associées à apoB, et peut renforcer l'effet hypolipidémiant d'un autre agent hypolipidémiant lorsqu'il est utilisé avec cet autre agent. Lorsqu'il est combiné avec un autre agent hypolipidémiant, le médicament selon l'invention est utilisé en tant qu'agent renforçant l'effet hypolipidémiant, dans le traitement de l'hypercholestérolémie familiale et de l'hyperlipémie rebelle accompagnant le diabète. |
---|---|
AbstractList | It is intended to provide a drug which has an excellent effect of inhibiting the secretion of apoB-related lipoproteins and enhances the lipid-lowering effect of another lipid-lowering agent, i.e., an agent enhancing lipid-lowering effect. It is found out that a derivative having tetrahydropyran represented by the following general formula (I): (I) wherein each symbol is as defined in the description; has a potent activity of inhibiting the secretion of apoB-related lipoproteins and can enhance the lipid-lowering effect of another lipid-lowering agent, when used together with such an agent. When used together with another lipid-lowering agent, the above drug is useful as an agent enhancing lipid-lowering effect for familial hypercholesterolemia and a remedy for intractable hyperlipemia with the coincidence of diabetes.
L'invention concerne un agent renforçant l'effet hypolipidémiant, à savoir un médicament présentant un excellent effet d'inhibition de la sécrétion des lipoprotéines associées à apoB, et renforçant l'effet hypolipidémiant d'un autre agent hypolipidémiant. Selon l'invention, un dérivé contenant du tétrahydropyrane, représenté par la formule générale (I) : (I), dans laquelle chaque symbole est tel que défini dans la description, présente une activité puissante d'inhibition de la sécrétion des lipoprotéines associées à apoB, et peut renforcer l'effet hypolipidémiant d'un autre agent hypolipidémiant lorsqu'il est utilisé avec cet autre agent. Lorsqu'il est combiné avec un autre agent hypolipidémiant, le médicament selon l'invention est utilisé en tant qu'agent renforçant l'effet hypolipidémiant, dans le traitement de l'hypercholestérolémie familiale et de l'hyperlipémie rebelle accompagnant le diabète. |
Author | MIURA, MASANORI KUBOTA, HIDEKI SUGA, AKIRA MORITANI, HIROSHI SASUGA, DAISUKE |
Author_xml | – fullname: MIURA, MASANORI – fullname: SUGA, AKIRA – fullname: MORITANI, HIROSHI – fullname: SASUGA, DAISUKE – fullname: KUBOTA, HIDEKI |
BookMark | eNrjYmDJy89L5WRQdXR39QtRcPXzcPRz9vRzV_DxDPB00fXxdw0PAnFd3dxcnUN4GFjTEnOKU3mhNDeDsptriLOHbmpBfnxqcUFicmpeakl8uL-RgYGpgamhsYWRo6ExcaoAA7oluw |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | AGENT RENFORÇANT L'EFFET HYPOLIPIDEMIANT |
Edition | 7 |
ExternalDocumentID | WO2005051382A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_WO2005051382A13 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 11:47:44 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English French Japanese |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_WO2005051382A13 |
Notes | Application Number: WO2004JP17899 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20050609&DB=EPODOC&CC=WO&NR=2005051382A1 |
ParticipantIDs | epo_espacenet_WO2005051382A1 |
PublicationCentury | 2000 |
PublicationDate | 20050609 |
PublicationDateYYYYMMDD | 2005-06-09 |
PublicationDate_xml | – month: 06 year: 2005 text: 20050609 day: 09 |
PublicationDecade | 2000 |
PublicationYear | 2005 |
RelatedCompanies | MIURA, MASANORI KUBOTA, HIDEKI SUGA, AKIRA YAMANOUCHI PHARMACEUTICAL CO., LTD MORITANI, HIROSHI SASUGA, DAISUKE |
RelatedCompanies_xml | – name: MORITANI, HIROSHI – name: SUGA, AKIRA – name: KUBOTA, HIDEKI – name: YAMANOUCHI PHARMACEUTICAL CO., LTD – name: MIURA, MASANORI – name: SASUGA, DAISUKE |
Score | 2.7063158 |
Snippet | It is intended to provide a drug which has an excellent effect of inhibiting the secretion of apoB-related lipoproteins and enhances the lipid-lowering effect... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
Title | AGENT ENHANCING LIPID-LOEWRING EFFECT |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20050609&DB=EPODOC&locale=&CC=WO&NR=2005051382A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQSTNISjZPNUvRtTQAHaqdbGasm2iQbKJrlmSeaJJsngZsQ4PGO3z9zDxCTbwiTCOYGHJge2HA54SWgw9HBOaoZGB-LwGX1wWIQSwX8NrKYv2kTKBQvr1biK2LGqx3DDouz1LNxcnWNcDfxd9ZzdkZ2G9T8wuCyJmCDtxzBPaVWEENadBJ-65hTqB9KQXIlYqbIANbANC8vBIhBqasRGEGTmfY3WvCDBy-0ClvIBOa-4pFGFQd3V39QhRc_TxAq-v83BWAvXJPF10ff9dw0JoGBWCb09U5RJRB2c01xNlDF2hfPNx78eH-yI4zFmNgAXb8UyUYFMzTLFItQdOCacZpJonmpsBAtDBPSUoCNsoMEtMsDCQZZPCZJIVfWpqBC3wMKWhEwVKGgaWkqDRVFljBliTJgcMFAANYea8 |
link.rule.ids | 230,309,786,891,25594,76906 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFOebTsWPqQW1b8VCP9I-DNnadJ226ZDq9lbargFFdLiK_76XuOqe9hYSyMfB5e53d_kF4JrrRUkqe665uiDVLm1Dy_XS1OyC5GZJOPrQIt4RMzt8Mu9n1qwFb81bGMkT-i3JEVGjStT3Wt7Xi_8gli9rK5e3xQt2fdwFad9XG3Qs6PJc1R_26STxE0_1PMRtKnv8HbME4d4AsdIWEfy8wnl6Hop3KYt1oxLswfYE53uv96H1mneh4zV_r3VhJ16lvLG50r7lAdwMRpSlCmWhqK5jIwVR-djXooRORU2Dgj4n9dJDuApo6oUarpf9HS-bJuubM46gjcC_OgaFcKdyRVqQG9zMiYVCdMi8KNAp03Pu6CfQ2zTT6ebhS-iEaRxl0Zg9nMGupCQV0QW3B-3686s6R2NbFxdSRj_b7Hyc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=AGENT+ENHANCING+LIPID-LOEWRING+EFFECT&rft.inventor=MIURA%2C+MASANORI&rft.inventor=SUGA%2C+AKIRA&rft.inventor=MORITANI%2C+HIROSHI&rft.inventor=SASUGA%2C+DAISUKE&rft.inventor=KUBOTA%2C+HIDEKI&rft.date=2005-06-09&rft.externalDBID=A1&rft.externalDocID=WO2005051382A1 |